Ole Kirk researcher
Kirk, Ole f. 1967-02-24
Kirk, Ole
Kirk, Ole, 1967-
VIAF ID: 63361590 (Personal)
Permalink: http://viaf.org/viaf/63361590
Preferred Forms
- 100 1 _ ‡a Kirk, Ole
-
- 100 1 _ ‡a Kirk, Ole, ‡d 1967-
- 100 0 _ ‡a Ole Kirk ‡c researcher
4xx's: Alternate Name Forms (1)
Works
Title | Sources |
---|---|
Effects of highly active antiretroviral therapy among HIV-infected patients | |
EuroSIDA, 1999: | |
EuroSIDA - a multicentre study | |
The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study | |
Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? | |
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? | |
K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine | |
Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. | |
Late presentation of HIV infection: a consensus definition | |
Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better | |
Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C | |
Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals | |
Long-term exposure to combination antiretroviral therapy and risk of death from specific causes | |
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. | |
Loss to follow-up in an international, multicentre observational study | |
Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational c | |
Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine | |
[Major breakthroughs in the medical treatment] | |
Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America | |
Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe | |
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina | |
Myocardial Impairment and Acute Respiratory Distress Syndrome in Hospitalized Patients With Coronavirus Disease-2019: The ECHOVID-19 Study | |
A new health care index predicts short term mortality for TB and HIV co-infected people | |
Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study | |
O212 Rate of change in CD4 counts in patients with stable HIV viremia | |
O313 Relation between adverse effects of ARV treatment and underlying risk in number needed to treat to harm (NNTH) – myocardial infarction and abacavir use | |
O332 Opportunistic infections in immunocompromised but virologically suppressed HIV-1 infected patients | |
Penicillin as empirical therapy for patients hospitalised with community acquired pneumonia at a Danish hospital. | |
Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy | |
Predictive value of prostate-specific antigen for prostate cancer: a nested case-control study in EuroSIDA. | |
Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons | |
Predictors of hypertension and changes of blood pressure in HIV-infected patients. | |
Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study | |
The prevalence and predictive value of dipstick urine protein in HIV-positive persons in Europe | |
Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons | |
A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors | |
Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression | |
Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe | |
Regional differences in self-reported HIV care and management in the EuroSIDA study | |
Relating protease inhibitor resistance at time of virological failure with drug exposure. | |
Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies | |
Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir | |
Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study | |
Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001. | |
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study | |
SARS-CoV-2 infection among patients with haematological disorders: Severity and one-month outcome in 66 Danish patients in a nationwide cohort study | |
Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe | |
Serum creatinine and estimated glomerular filtration rates in HIV positive and negative adults in Ethiopia | |
Severe bacterial non-aids infections in HIV-positive persons: incidence rates and risk factors. | |
Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe | |
Stability of hepatitis C virus | |
A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe | |
TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortality | |
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. | |
Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration | |
TTV viral load as a marker for immune reconstitution after initiation of HAART in HIV-infected patients | |
Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors | |
Tuberculosis Drug Susceptibility, Treatment, and Outcomes for Belarusian HIV-Positive Patients with Tuberculosis: Results from a National and International Laboratory | |
Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study | |
Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial | |
Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study | |
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration | |
Variation in antiretroviral treatment (ART) coverage and virological suppression among three HIV key populations | |
Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients | |
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study | |
Withholding primary PcP prophylaxis in virologically suppressed HIV patients: An emulation of a pragmatic trial in COHERE |